Cases of Patients Treated in Countries With Limited Resources and Discussed by Experts of the International CML Foundation (iCMLf)-Case No. 2: Treatment-Free Remission After 9 Years of Imatinib Treatment Without Prior Achievement of Sustained Deep Molecular Response. [PDF]
Case Rep Oncol MedMichalowski MB +5 more
europepmc +1 more source
Fluorescence in situ hybridization for the BCR–ABL fusion gene in a patient with imatinib mesylate‐resistant chronic myelogenous leukaemia in extramedullary blast crisis [PDF]
, 2003 Takehiko Mori +3 more
openalex +1 more source
Impact of Mutation Profile on Outcomes of Neoadjuvant Therapy in GIST. [PDF]
Cancers (Basel)Mohammadi M +13 more
europepmc +1 more source
Functional consequence of MDR1 expression on imatinib intracellular concentrations [PDF]
, 2003 Nicolas Widmer +3 more
openalex +1 more source
Body mass index affects imatinib exposure: Real-world evidence from TDM with adaptive dosing. [PDF]
Fundam Clin PharmacolMaroselli P +7 more
europepmc +1 more source
Imatinib mesylate elicits positive clinical response in atypical chronic myeloid leukemia involving the platelet-derived growth factor receptor beta [PDF]
, 2003 Juan Luis Garcı́a +6 more
openalex +1 more source
Primary imatinib failure rescued by dasatinib and maintained by reintroduction of imatinib
Revista Brasileira de Hematologia e Hemoterapia, 2017 Kumar,Rajiv, Kapoor,Rajan
openaire +5 more sources
Identifying Key Factors Influencing Non-adherence to Imatinib Therapy in Patients With Chronic Myeloid Leukemia. [PDF]
CureusPandey D, Chugh P, Chaudhry S.
europepmc +1 more source
CNS and Cutaneous Involvement in Patients With Chronic Myeloid Leukemia Treated With Imatinib in Hematologic Complete Remission: Two Case Reports [PDF]
, 2003 Elisabetta Abruzzese +10 more
openalex +1 more source